$29.55
0.87% day before yesterday
Nasdaq, Dec 27, 10:12 pm CET
ISIN
IE00B56GVS15
Symbol
ALKS

Alkermes Plc Stock price

$29.55
+0.23 0.78% 1M
+5.26 21.66% 6M
+1.81 6.52% YTD
+1.49 5.31% 1Y
+6.22 26.66% 3Y
+9.45 47.00% 5Y
-27.96 48.62% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.26 0.87%
ISIN
IE00B56GVS15
Symbol
ALKS
Sector
Industry

Key metrics

Market capitalization $4.78b
Enterprise Value $4.24b
P/E (TTM) P/E ratio 15.05
EV/FCF (TTM) EV/FCF 13.45
EV/Sales (TTM) EV/Sales 2.82
P/S ratio (TTM) P/S ratio 3.18
P/B ratio (TTM) P/B ratio 3.70
Revenue growth (TTM) Revenue growth -5.37%
Revenue (TTM) Revenue $1.51b
EBIT (operating result TTM) EBIT $312.58m
Free Cash Flow (TTM) Free Cash Flow $315.22m
Cash position $908.86m
EPS (TTM) EPS $1.96
P/E forward 14.79
P/S forward 3.17
EV/Sales forward 2.81
Short interest 12.64%
Show more

Is Alkermes Plc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Alkermes Plc Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Alkermes Plc forecast:

8x Buy
62%
4x Hold
31%
1x Sell
8%

Analyst Opinions

13 Analysts have issued a Alkermes Plc forecast:

Buy
62%
Hold
31%
Sell
8%

Financial data from Alkermes Plc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
1,505 1,505
5% 5%
100%
- Direct Costs 268 268
6% 6%
18%
1,238 1,238
5% 5%
82%
- Selling and Administrative Expenses 628 628
0% 0%
42%
- Research and Development Expense 257 257
33% 33%
17%
352 352
21% 21%
23%
- Depreciation and Amortization 40 40
48% 48%
3%
EBIT (Operating Income) EBIT 313 313
45% 45%
21%
Net Profit 333 333
55% 55%
22%

In millions USD.

Don't miss a Thing! We will send you all news about Alkermes Plc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Alkermes Plc Stock News

Neutral
PRNewsWire
about one month ago
DUBLIN , Nov. 25, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in two upcoming investor conferences. 7th Annual Evercore ISI HealthCONx Conference Date/Time: Tuesday, Dec. 3, 2024 at 10:25 a.m.
Positive
Seeking Alpha
about one month ago
Alkermes has shifted from royalty-based revenues to proprietary product sales, driven by strong growth in Lybalvi, Vivitrol, and Aristada. ALKS 2680, a Phase 2 orexin-2 receptor agonist for narcolepsy and hypersomnia, represents a transformative opportunity in a $7.3 billion market by 2032. With $908.9 million in liquidity and a positive cash flow of $73.3 million in Q3, Alkermes can effectivel...
Neutral
Investors Business Daily
about one month ago
The top five biotech stocks today have several commonalities. Among them are strong ratings.
More Alkermes Plc News

Company Profile

Alkermes Plc is a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. Its products include Aristada, which is used for the treatment of schizophrenia in adults; and Vivitrol, which is an injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. The company was founded on May 4, 2011 and is headquartered in Dublin, Ireland.

Head office Ireland
CEO Richard Pops
Employees 2,100
Founded 2011
Website www.alkermes.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today